Search clinical trials for: Lantus (glargine)

Total 1014 results

Sanofi

Completed

Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Healthy Volunteers

Germany
Sanofi

Completed

Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment (Transition II)

Diabetes Mellitus, Type 2

France
Xijing Hospital

Unknown

A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use

Type 2 Diabetes Mellitus

China
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Eli Lilly and Company

Completed

Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Puerto Rico
IRCCS San Raffaele

Terminated

Normalization of Fasting Glucose and the Incidence of Restenosis After Peripheral Angioplasty (LIMBISCH)

Type 2 Diabetes Mellitus | Peripheral Vascular Disease

Italy
Universidad Nacional de Asunción

Completed

Basal Bolus Versus Human Insulin in Hospitalized Patients With Diabetes in Paraguay

Hyperglycemia | Diabetes

Paraguay
Sanofi

Completed

Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)

Type 2 Diabetes Mellitus

China
Sanofi

Completed

Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Germany
Northwestern University

Terminated

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

Insulin Resistance, Diabetes | Hyperglycemia Steroid-induced

United States
Sanofi

Completed

Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial

Diabetes Mellitus, Type 2

United States, Brazil, Netherlands, Portugal, Spain, India, Austria, Egypt, Greece, Israel, Mexico, United Kingdom, Korea, Republic of, Hong Kong, Colombia, Lebanon
Sanofi

Completed

Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients (EASIE)

Diabetes Mellitus, Type 2

United States, Brazil, Netherlands, Portugal, Spain, Turkey, India, Austria, Egypt, Greece, Israel, Mexico, United Kingdom, Korea, Republic of, Hong Kong, Colombia, Lebanon
Mira Zuidgeest
Sanofi; Innovative Medicines Initiative; IMI Trials@Home consortium

Recruiting

Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL) (RADIAL)

Diabetes Mellitus, Type 2

United Kingdom, Denmark, Germany
Eli Lilly and Company

Completed

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus (AWARD-CHN2)

Type 2 Diabetes Mellitus

China, Mexico, Korea, Republic of, Russian Federation
Sanofi

Completed

Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy

Type 2 Diabetes Mellitus

United States
Changhua Christian Hospital

Recruiting

Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care

Diabetic Ketoacidosis | Hyperglycaemic Crisis in Diabetes Mellitus | Hyperglycaemic Hyperosmolar Nonketotic Syndrome

Taiwan
University Hospital Tuebingen

Terminated

Effects of Insulin Glargine and Lixisenatide on the Brain (Lixibrain01)

Diabetes Mellitus, Type 2

Germany
Sanofi

Completed

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus (EDITION JUNIOR)

Type 1 Diabetes Mellitus

France, Czechia, Chile, Israel, Spain, Hungary, Mexico, Serbia, Japan, Canada, Brazil, Sweden, Denmark, Argentina, United States, Bulgaria, Germany, Italy, Latvia, North Macedonia, Poland, Romania, Russian Federation, United Kingdom
The University of Texas Medical Branch, Galveston

Terminated

Fatty Liver Study in Patients With Type II Diabetes

Type II Diabetes | Nonalcoholic Fatty Liver

United States
Sanofi

Completed

Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus

Type1 Diabetes

Germany
Sanofi

Completed

A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period (INITIATION)

Type 2 Diabetes Mellitus

China
Sanofi

Completed

Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM) (LixilanOne CAN)

Type 2 Diabetes Mellitus

Canada
Medical University of Graz

Completed

A Trial to Investigate Efficacy and Usability of Published Best Practice to Control Glycaemia

Diabetes Mellitus, Type 2

Austria
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan (LIXILAN JP-O2)

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL (TOP1)

Type I Diabetes Mellitus

Brazil
Shenzhen Second People's Hospital

Unknown

Study on the Feasibility of Community Doctors Guided by Specialists to Use Basic Insulin

Type 2 Diabetes
Novo Nordisk A/S

Completed

Safety of NNC 0123-0000-0338 in Healthy Subjects

Healthy | Diabetes

Germany
Merck Sharp & Dohme LLC

Completed

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
Sanofi

Completed

Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo (AUTOMATIX)

Type 2 Diabetes Mellitus

Germany, United Kingdom
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs (CONCLUDE)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Canada, Denmark, Hungary, Serbia, Germany, Greece, Romania, Estonia, Norway
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Canada, United Kingdom, Ireland, France, South Africa, Ukraine
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Netherlands, Hungary, France, Bulgaria, Canada, Romania
Novo Nordisk A/S

Completed

A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Austria
Biodel

Completed

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

Diabetes Mellitus

United States
Novo Nordisk A/S

Recruiting

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

Obesity | Diabetes Mellitus, Type 2

United States, Spain, Portugal, Italy, Greece, Romania, Slovakia, Czechia, South Africa, Ukraine
Sanofi

Active, not recruiting

Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs (SAFEGUARD)

Type 2 Diabetes Mellitus

India
Sanofi

Completed

Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure (GAUDI)

Type 2 Diabetes Mellitus

Japan
Sun Yat-sen University

Completed

Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects (LIGHT-ON)

Non-alcoholic Fatty Liver Disease

China
Vancouver General Hospital

Terminated

Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia (PTHG)

Post-Transplant Glucocorticoid Induced Diabetes

Canada
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus

Healthy | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
University of Pittsburgh
Sanofi

Completed

Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings

Hyperglycemia | Type 2 Diabetes

United States
AstraZeneca

Completed

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Universidad de Guanajuato

Completed

Insulin Schemes for Type 2 Diabetes Control

Type 2 Diabetes Mellitus

Mexico
Sanofi

Completed

Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost. (ATOS)

Diabetes

Peru, Ukraine, Colombia, Egypt, India, Indonesia, Israel, Jordan, Kuwait, Lebanon, Mexico, Philippines, Russian Federation, Saudi Arabia, Singapore, Taiwan, Thailand, United Arab Emirates
Sanofi

Completed

Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1

Type 1 Diabetes Mellitus

Germany

3

Subscribe